Intravesical Mitomycin C Therapy for Superficial Bladder Cancer. Report of a Multicentre Phase II Study
- 31 January 1985
- journal article
- research article
- Published by Wiley in British Journal of Urology
- Vol. 57 (1), 37-39
- https://doi.org/10.1111/j.1464-410x.1985.tb08980.x
Abstract
Patients (25) with early transitional cell carcinoma of the bladder (Tis Ta T1) received intravesical instillations of 40 mg mitomycin C in 40 ml water weekly for 7 wk. The overall response rate was 70% (complete response 40%). In patients with Ta tumors the response rate was 86%. Minor toxic side effects occurred in 4 patients and only 1 patient was unable to complete the course of treatment because of side effects.This publication has 7 references indexed in Scilit:
- A Phase II Study of lntravesical Mitomycin C in the Treatment of Superficial Bladder CancerBritish Journal of Urology, 1983
- Prognostic Factors in Non-infiltrating Carcinoma of the Bladder: A Preliminary ReportBritish Journal of Urology, 1982
- Ta and T1 Bladder Cancer: Location, Recurrence and Progression†British Journal of Urology, 1982
- Prognostic Parameters in Superficial Bladder Cancer: An Analysis of 315 CasesJournal of Urology, 1982
- The Effect of Mitomycin C on Superficial Bladder CancerJournal of Urology, 1981
- The Natural History of Papillary Transitional Cell Carcinoma of the Bladder and its Treatment in an Unselected Population on the Basis of Histologic GradingJournal of Urology, 1978
- THIOTEPA IN THE TREATMENT OF TUMOURS OF THE BLADDERThe Lancet, 1961